Florence Moulin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Florence Moulin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Anne Scemla
Service de Néphrologie - Transplantation, Hôpital Necker-Enfants malades, Groupe hospitalier AP-HP.Centre - Université Paris Cité, Paris, France; RTRS Centaure, Labex Transplantex, Université Paris Cité, France
2 shared publications- Julie Toubiana
Service Pédiatrie Générale et Maladies Infectieuses, Hôpital Necker-Enfants malades, AP-HP, Université Paris Cité
2 shared publications - Mehdi Oualha
Pediatric Intensive Care Unit, Necker Hospital, APHP, Centre - Paris University, Paris, France
2 shared publications - Michael Levy
Department of Surgical Intermediate Care, Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
2 shared publications - Pierre Frange
Microbiology department, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France; Université Paris Cité, URP 7328 FETUS, Paris, France
2 shared publications - Sylvain Renolleau
Réanimation Et Surveillance Continue Médico-Chirurgicales Pédiatriques, Hôpital Necker-Enfants Malades, AP-HP, Université de Paris, Paris, France
2 shared publications
Latest Publications
- 26 June 2022
- Published by Elsevier in Journal of Infection
- Vol. 85 (4) , 436-480
No durable impact of COVID-19 measures on the hospital burden of respiratory syncytial virus (France, 2018–2022)
- 26 June 2022
- Published by Elsevier in Journal of Infection
- Vol. 85 (4) , 436-480
No durable impact of COVID-19 measures on the hospital burden of respiratory syncytial virus (France, 2018–2022)
- 18 June 2021
- Published by Springer Nature in Pediatric Drugs
- Vol. 23 (4) , 395-401
Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children
Objectives This study aimed to assess the incidence of amikacin plasma peak concentration (Cmax) below 60 mg·L−1 in critically ill children receiving an amikacin dosing regimen of 30 mg kg−1·day−1. Secondary objectives were to identify factors associated with low Cmax and to assess the incidence of acute kidney injury (AKI). Methods A retrospective observational study was performed in two French pediatric intensive care units. All admitted children who received 30 mg·kg−1 amikacin and had a Cmax measurement were eligible. Clinical and biological data, amikacin dose, and concentrations were collected. Results In total, 30 patients were included, aged from 3 weeks to 7 years. They received a median amikacin dosage of 30 mg kg−1·day−1 (range 29–33) based on admission body weight (BW), corresponding to 27 mg kg−1·day−1 (range 24–30) based on actual BW. Cmax was < 60 mg·L−1 in 21 (70%) children and none had a Cmax ≥ 80 mg·L−1. Among the 15 patients with a measured minimum inhibitory concentration (MIC), 13 (87%) had a Cmax/MIC ratio > 8. Univariate analysis showed that factors associated with Cmax < 60 mg·L−1 were high estimated glomerular filtration rate (p = 0.015) and low blood urea concentration (p = 0.001). AKI progression or occurrence was observed after amikacin administration in two (7%) and six (21%) patients, respectively. Conclusions Despite the administration of the maximal recommended amikacin dose, Cmax was below the pharmacokinetic target in 70% of our pediatric population. Further studies are needed to develop a pharmacokinetic model in a population of critically ill children to optimize target attainment.
- 18 June 2021
- Published by Springer Nature in Pediatric Drugs
- Vol. 23 (4) , 395-401
Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children
Objectives This study aimed to assess the incidence of amikacin plasma peak concentration (Cmax) below 60 mg·L−1 in critically ill children receiving an amikacin dosing regimen of 30 mg kg−1·day−1. Secondary objectives were to identify factors associated with low Cmax and to assess the incidence of acute kidney injury (AKI). Methods A retrospective observational study was performed in two French pediatric intensive care units. All admitted children who received 30 mg·kg−1 amikacin and had a Cmax measurement were eligible. Clinical and biological data, amikacin dose, and concentrations were collected. Results In total, 30 patients were included, aged from 3 weeks to 7 years. They received a median amikacin dosage of 30 mg kg−1·day−1 (range 29–33) based on admission body weight (BW), corresponding to 27 mg kg−1·day−1 (range 24–30) based on actual BW. Cmax was < 60 mg·L−1 in 21 (70%) children and none had a Cmax ≥ 80 mg·L−1. Among the 15 patients with a measured minimum inhibitory concentration (MIC), 13 (87%) had a Cmax/MIC ratio > 8. Univariate analysis showed that factors associated with Cmax < 60 mg·L−1 were high estimated glomerular filtration rate (p = 0.015) and low blood urea concentration (p = 0.001). AKI progression or occurrence was observed after amikacin administration in two (7%) and six (21%) patients, respectively. Conclusions Despite the administration of the maximal recommended amikacin dose, Cmax was below the pharmacokinetic target in 70% of our pediatric population. Further studies are needed to develop a pharmacokinetic model in a population of critically ill children to optimize target attainment.
- Open Access
- 16 June 2021
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 30 (Hors-série) , 53-68
Le SARS-CoV-2 en réanimation pédiatrique
In a lesser extent than adults Intensive Care Units (ICUs), Pediatric ICUs (PICUs) had to deal with the SARS-CoV-2 pandemic. Pediatric intensivists managed serious pediatric forms of primary infections and then in a second stage, post-infectious systemic inflammatory attacks. Some of them helped with the management of adults with a severe form of SARS-CoV-2. Therefore, they had to adapt in record time. In this review, we report (i) the literature data on these two severe pediatric forms, the primary infection and the systemic inflammatory manifestations associated with SARS-CoV-2; (ii) the experience of PICUs in the management of critically ill adults with SARS-CoV-2 infection and (iii) and the impact of the pandemic on the place of families of children in critical situation in PICUs.
- 16 June 2021
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 30 (Hors-série) , 53-68
Open AccessLe SARS-CoV-2 en réanimation pédiatrique
In a lesser extent than adults Intensive Care Units (ICUs), Pediatric ICUs (PICUs) had to deal with the SARS-CoV-2 pandemic. Pediatric intensivists managed serious pediatric forms of primary infections and then in a second stage, post-infectious systemic inflammatory attacks. Some of them helped with the management of adults with a severe form of SARS-CoV-2. Therefore, they had to adapt in record time. In this review, we report (i) the literature data on these two severe pediatric forms, the primary infection and the systemic inflammatory manifestations associated with SARS-CoV-2; (ii) the experience of PICUs in the management of critically ill adults with SARS-CoV-2 infection and (iii) and the impact of the pandemic on the place of families of children in critical situation in PICUs.
- Open Access
- 1 June 2020
- Published by Elsevier in Infection Prevention in Practice
- Vol. 2 (2) , 100041
Preventing respiratory syncytial virus infections in hospitalized children and adults: should we do better?
- 1 June 2020
- Published by Elsevier in Infection Prevention in Practice
- Vol. 2 (2) , 100041
Open AccessPreventing respiratory syncytial virus infections in hospitalized children and adults: should we do better?
- 12 June 2007
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 167 (4) , 435-436
The burden of respiratory viral disease in hospitalized children in Paris
A virus was identified in 464 out of 1,212 patients, 8 days to 16 years of age, who were admitted to the hospital in Paris during a 3 year period. Respiratory syncytial virus (RSV) was found in 428 patients, 74% were younger than 6 months with bronchiolitis, and 6% were older than 2 years. RSV was the first virus isolated in all patients and in those with pneumonia or asthma. The low number of admissions due to parainfluenzae viruses is characteristic of this area compared to other countries.
- 12 June 2007
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 167 (4) , 435-436
The burden of respiratory viral disease in hospitalized children in Paris
A virus was identified in 464 out of 1,212 patients, 8 days to 16 years of age, who were admitted to the hospital in Paris during a 3 year period. Respiratory syncytial virus (RSV) was found in 428 patients, 74% were younger than 6 months with bronchiolitis, and 6% were older than 2 years. RSV was the first virus isolated in all patients and in those with pneumonia or asthma. The low number of admissions due to parainfluenzae viruses is characteristic of this area compared to other countries.